Pharma Deals Review, Vol 2005, No 55 (2005)

Font Size:  Small  Medium  Large

Genzyme Reacquires Arthritis Pain Treatment from Wyeth

Business Review Editor

Abstract


Genzyma reacquired the sales and marketing rights to Synvisc® (hylan G-F 20), an arthritis pain treatment, from Wyeth. The deal could be worth up to US$415 M to Wyeth.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.